Frank G A, Kuznetsova O A, Zavalishina L E, Andreeva Yu Yu, Olyushina E M, Vinogradov I Yu, Vinogradov M I, Kulikov E P, Shomova M V
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia.
Regional Clinical Oncology Dispensary, Ryazan, Russia.
Arkh Patol. 2019;81(2):3-9. doi: 10.17116/patol2019810213.
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.
The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.
Differences were found in the incidence of carcinomas with PD-L1 expression in tumor cells depending on the molecular genetic type: there was a positive PD-L1 status in luminal B, HER2-negative tumors in 4 (14.81%) of 27 cases and in triple-negative tumors in 17 (37.78%) of 45 cases. An analysis of tumors after neoadjuvant therapy revealed a positive PD-L1-status in tumor cells in 1 of 18 patients with a moderate residual tumor load and in 6 of 13 with a high residual tumor load (5.56 and 46.15%, respectively), as estimated by the RCB system.
The positive PD-L1 status in triple-negative breast cancer was determined more than 2 times as frequently as in luminal B, HER2-negative breast cancer (37.78 and 14.81%). There was a considerable correlation between the high residual tumor load and the positive tumor PD-L1 status.
研究程序性死亡受体配体1（PD-L1）在三阴性及腔面B型、人表皮生长因子受体2（HER2）阴性乳腺癌中的表达，并评估肿瘤PD-L1状态与疾病预后的相关性。
采用免疫组化方法对72例乳腺癌患者原发肿瘤的PD-L1状态进行研究。
根据分子遗传类型，肿瘤细胞中PD-L1表达的癌发生率存在差异：27例腔面B型、HER2阴性肿瘤中有4例（14.81%）PD-L1状态为阳性，45例三阴性肿瘤中有17例（37.78%）PD-L1状态为阳性。新辅助治疗后肿瘤分析显示，根据残余癌负荷（RCB）系统评估，18例中度残余肿瘤负荷患者中有1例肿瘤细胞PD-L1状态为阳性，13例高度残余肿瘤负荷患者中有6例肿瘤细胞PD-L1状态为阳性（分别为5.56%和46.15%）。
三阴性乳腺癌中PD-L1阳性状态的确定频率是腔面B型、HER2阴性乳腺癌的2倍多（37.78%和14.81%）。高残余肿瘤负荷与肿瘤PD-L1阳性状态之间存在显著相关性。
